ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

BACKGROUND: In non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs), higher blood tumor mutational burden (bTMB) was usually associated with better progression-free survival (PFS) and objective response rate (ORR). However, the association between bTMB and overal...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Wei, Wang, Zhi-Jie, Zhang, Kai, Li, Bing, Cai, Yi-Ran, Wen, Feng-Cai, Zhang, Ding, Bai, Yue-Zong, Zhang, Xue-Yan, Wang, Shu-Yuan, Cheng, Lei, Zhong, Hua, Liu, Li, Wang, Jie, Han, Bao-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069852/
https://www.ncbi.nlm.nih.gov/pubmed/35509036
http://dx.doi.org/10.1186/s12916-022-02360-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069852/
https://www.ncbi.nlm.nih.gov/pubmed/35509036
http://dx.doi.org/10.1186/s12916-022-02360-x

Ejemplares similares